The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miletic, V. D.
Right arrow Articles by Frank, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miletic, V. D.
Right arrow Articles by Frank, M. M.

The Journal of Immunology, Vol 156, Issue 2 749-757, Copyright © 1996 by American Association of Immunologists

ARTICLES

Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes

VD Miletic, CG Hester and MM Frank
Duke University Medical Center, Department of Pediatrics, Durham, NC 27710, USA.

Intravenous Ig, composed principally of IgG, prevents complement attack by inhibiting C3 and C4 uptake onto target cells and tissues. Using two different models, Ab-sensitized SRBC and BSA-anti BSA solid phase immune complexes, we have examined the complement inhibitory capacity of three Ig classes (IgG, IgM, IgA) focussing on inhibition of C4 uptake. It was found that on both a weight and molar basis, monomeric serum IgA and IgM were far more active than IgG (weight efficiency ratios were 1.0, 20.8, and 236.3, and molar efficiency ratios 1.0, 24.0, and 1382.9 for polyclonal IgG, IgA1, and IgM, respectively). Monoclonal IgM were less active than polyclonal IgM (50% inhibition was achieved in SRBC model by 0.022, 0.30, 1.6, and 1.6 mg/ml of polyclonal IgM and monoclonal IgM from patients Lew, Will, and Pri). Secretory IgA was less active than serum IgA1 and similar in inhibitory activity to IgG (weight and molar efficiency ratios 1.5 and 0.6 compared with IgG). All tested preparations were less active in the solid phase immune complex model than in the sensitized cell model. A mixture of Igs of different isotypes was somewhat more active than any isotype alone. These results suggest that polyclonal serum IgA and IgM can also be considered for active therapy in diseases accompanied by the activation of classical complement pathway.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
W. T. Watford, J. R. Wright, C. G. Hester, H. Jiang, and M. M. Frank
Surfactant Protein A Regulates Complement Activation
J. Immunol., December 1, 2001; 167(11): 6593 - 6600.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Rieben, A. Roos, Y. Muizert, C. Tinguely, A. F. Gerritsen, and M. R. Daha
Immunoglobulin M-Enriched Human Intravenous Immunoglobulin Prevents Complement Activation In Vitro and In Vivo in a Rat Model of Acute Inflammation
Blood, February 1, 1999; 93(3): 942 - 951.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Wagner, J. L. Platt, and M. M. Frank2
High Dose Intravenous Immunoglobulin Does Not Affect Complement-Bacteria Interactions
J. Immunol., February 15, 1998; 160(4): 1936 - 1943.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
T. E. Mollnes and M. Harboe
Recent Advances: Clinical immunology
BMJ, June 8, 1996; 312(7044): 1465 - 1469.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.